The Biotech of Tomorrow

Picture the biotech that did everything right. It bought the licenses. It wrote the responsible-use policy. It ran the pilots, counted the hours saved, and put the numbers in a board deck. A year later it was faster. It was also the same company it had been the year before. Faster at the same documents. Faster at the same meetings. Faster at the same decisions, in the same order, for the same reasons.

That is not transformation. That is efficiency wearing transformation’s clothes.

Almost everyone is in this trap. The reason is the question they started with: how can AI help us do our existing work faster? Reasonable question. It also guarantees you rebuild the past at a discount.

This publication starts from a different one. What would we build if today’s capabilities had existed when this company, this function, this workflow was first designed?

That swap is the whole game. It is the line between an AI-enabled biotech and an AI-native one.

The wrong debate

Walk into most strategy rooms and you will hear an argument about models. Which foundation model. Which vendor. Build or buy the copilot. The choices matter. But they do not decide your future, and pretending they do has a cost. It lets everyone feel busy while the company stands still.

The model is not the transformation. The organization is the transformation.

A frontier model behind a login is not a new company. A thousand licenses are not a new company. Three hundred pilots are not a new company. Those are inputs. The output is an institution that spots a new capability, decides where it changes the work, gives people permission to act, redesigns the workflow around it, and can do it again next quarter. That chain, from raw capability to real advantage, is the product. Everything else is a demo.

Why efficiency is a dead end

Efficiency is seductive because it is safe. Hours saved is a clean number. It fits in a deck. It threatens no one.

That last part is why leaders reach for it. Redesigning work changes who does what, who decides, and whose job was built around a limit that no longer exists. Efficiency changes the numbers without changing the powerful. So the powerful pick efficiency, call it transformation, and wonder a year later why nothing feels different.

There is a deeper problem. When you automate a process, you freeze it. You take a workflow shaped by the limits of an older technology and pour concrete around it. Faster concrete. Still concrete. The handoffs, the review gates, the separations of duty that existed because information used to be expensive to move, are now fixed in place. You made yesterday permanent and called it progress.

Automating a broken process does not fix it. It gives you a faster broken process.

What AI-native means

Not a company where machines do everything. That is a boring fantasy. An AI-native biotech is built on an honest read of what people do well, what machines do well, what software can now carry, and how freely information can move when moving it costs almost nothing.

It keeps asking hard questions about its own design. Should this workflow exist as it does, or only because it always has? What still needs to be separate now that one system can hold all of it at once? Which decisions could happen earlier, with better evidence, if the right person saw the right thing in time? Where does human judgment matter more, not less?

None of those are questions about a model. They are questions about the institution. The technology is the catalyst. The organization is what changes.

So here is Monday morning. Pick one workflow that matters. Not the easy one. Not the one with the loudest AI request. One that carries real weight for the science or the business. Ask two questions. If we designed this today, knowing what these systems can do, what would we build? And what is actually stopping us, a hard constraint or a habit we inherited? The gap between those answers is your transformation. Everything else is a purchase order.

The map

Translational Intelligence is the capacity to turn new capability into durable advantage, again and again, as the technology keeps moving. That is the whole idea in one line. This publication builds it out.

The system that creates the capacity is Permission, People, and Programs. Permission is knowing where you are allowed to move. People is behavior change, the hardest and most decisive part. Programs is what you self-serve, buy, build, or redesign.

The role that makes it real is the AI Product Partner, the person who sits where capability meets the work and turns one into the other.

The destination is the AI-native biotech, the company that never stops translating, with no final form to reach.

Over the coming weeks I will take each of these apart, one issue at a time, with the frameworks and the language to use them. This is issue zero.

Why I am doing this

I have spent more than a decade in AI, most of it back when biotech saw it as a lab tool and nothing more. The last five years I have spent inside organizations, rebuilding them to meet the technology of today with an operating model built for tomorrow. Pandemic response at Google. A genotype-to-phenotype engineering team at Colossal. Enterprise AI transformation at Avidity. The same charge now at Alloy, through Vigilance. Different missions. Same work. And the same lesson every time: the technology is the easy part, and the human part is most of the job, by a wide margin.

People call my strategies surprisingly practical. The first time, it was a small dig, a way of saying they sounded too simple to matter. The next conversation, that person had tried it, and they had learned how hard simple is. Now we talk all the time about the human part, because that is where transformation is won or lost.

I get asked how to start almost every day. I want to help all of you, but I cannot sit with everyone. So this is my answer at scale. Nothing held back, nothing confidential. The gig is up. The edge was never a secret formula. It was the willingness to do the hard, human work of change, and then to do it again.

I called this translational intelligence on purpose. Because the more intelligently we all operate, the faster we translate science into therapies.

Cheers,
-Titus